Day: May 30, 2024

genasys image SAN DIEGO, May 30, 2024 (GLOBE NEWSWIRE) — Genasys Inc. (NASDAQ: GNSS), the global leader in Protective Communications, is pleased to announce that the San Diego County regional area announced yesterday at a press conference the official launch of Genasys Protect EVAC, a cutting-edge emergency alerting solution that will enable citizens to receive timely updates during emergency situations. With peak fire conditions looming ahead, this region wide collaboration aims to bolster emergency communication efforts and ensure the safety of all residents. EVAC, which is currently deployed across 70% of California, will serve as the primary tool for quickly disseminating critical public safety information, including severe weather alerts, evacuation notices, missing person reports, and other essential updates to affected...

REDWOOD CITY, Calif., May 30, 2024 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address mast cell driven diseases such as chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and asthma, today announced presentations of data from its preclinical and healthy volunteer studies of briquilimab, as well as trial-in-progress presentations from its BEACON and SPOTLIGHT clinical studies, at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2024, taking place May 31 – June 3 in Valencia, Spain. The two preclinical studies being presented at EAACI showed the potential of briquilimab in asthma and atopic dermatitis (AD), respectively. The asthma...

Next-generation-sequencing-based homologous recombination deficiency (HRD) assay based on QIAGEN’s QIAseq xHYB technology, QIAGEN Digital Insight solutions, and Myriad’s proprietary, FDA-approved MyChoice CDx® biomarkers QIAGEN to make kit-based HRD test available globally to support research and companion diagnostics development in collaboration with pharmaceutical partners enabling wider adoption and potential clinical indication expansion for MyChoice CDx Project builds on recently announced master collaboration agreement between the two companies VENLO, The Netherlands and SALT LAKE CITY, May 30, 2024 (GLOBE NEWSWIRE) — QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) and Myriad Genetics (NASDAQ: MYGN) today announced they will develop a globally distributable kit-based test for analyzing Homologous Recombination Deficiency...

LATHAM, N.Y., May 30, 2024 (GLOBE NEWSWIRE) — Plug Power Inc. (NASDAQ: PLUG), a global leader in comprehensive hydrogen solutions for the green hydrogen economy, invites investors and the general public to listen to a webcast of its annual meeting of stockholders on Wednesday, June 5, 2024, at 10:00 a.m. Eastern Time. The live webcast can be accessed through the Internet at www.virtualshareholdermeeting.com/PLUG2024. A general corporate overview and question and answer session is expected to follow the business portion of the annual meeting. The webcast can also be accessed directly from the Plug homepage (www.plugpower.com). A playback of the webcast will be available at www.plugpower.com for a period of time following the meeting. Stockholders of record will be able to submit questions on the day of the meeting in writing through...